Särnefält 2024: CEPI developed a CMC (Chemistry, Manufacturing, and Controls) framework to expedite the progression of vaccine candidates from research to deployment, reduce delays, mitigate risks, and optimize the overall development process.
Milestone
4.1.e
Review of preclinical candidates
In progress
High priority
Define selection criteria (e.g., including immunogenicity data from pre-immune animal models and considerations for global manufacturing capacity) for advancing preclinical influenza vaccine candidates into clinical evaluation.
Progress Highlights
Multiple public and private sector sponsors have selected a wide range of candidates for clinical trials based on positive results in animal models.